Ben Hickey, MBA
Ben Hickey is the chief commercial officer of Mirati Therapeutics, an oncology company focused on developing therapies that directly target the genetic and immunological drivers of cancer to create therapeutic benefits. At Mirati, he oversees all aspects of global commercialization, including pricing and access, sales & marketing, medical affairs, portfolio planning and patient advocacy. He has more than 20 years of industry experience leading commercial teams, including through global product launches for multiple oncology treatments. Previously, Mr. Hickey was chief commercial officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy of the company’s oncologic portfolio. Prior to this, he spent 17 years at Bristol Myers Squibb in roles of increasing responsibility, including general manager of the company in the United Kingdom and Ireland, leading a team of more than 300 people. He also served as vice president of marketing, immuno-oncology, where he oversaw the commercialization of YERVOY ®, a drug used to help prevent melanoma in adults, and managed the launch of OPDIVO®, an immuno-oncology drug. Mr. Hickey received both his MBA and B.S. in management from St. John’s University in New York.